What is the main business of Kolpharma?

The main business activity of Kolpharma focuses on wholesale of pharmaceutical goods.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on August 12, 2019.

Where is the headquarters located?

The headquarters is located at: ul. Pck 6, 44-105 Gliwice.

Who is on the management board?

The management board consists of: Georg Heinrich Zymella (President of the Management Board).

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of USD 183,727, representing an increase of 41.0% compared to 2024.

Yes, the company recorded a net profit of USD 19,514 in 2025, meaning the company increased its profit by 82.8%.

Which cost dominates operating expenses?

The largest operating cost category falls under other operating costs. This category amounted to USD 115,116 in 2025, representing 75% of all operating expenses.

Kolpharmasp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2019-08-12

Share capital

5,000.00 PLN

Activity description

Kolpharma supplies natural and herbal products, medical devices, dietary supplements, and cosmetics. Its range includes KnobiVital products, Breuss vegetable juice, ANABOX medicine organizers, and SANOHRA earplugs; it serves brick-and-mortar and online drugstores and pharmacies.

Registered address

ul. Pck 6, 44-105 Gliwice, Poland

Website

kolpharma.pl

Phone

Social media

Financials

Revenue history (in k)

Filing timeliness

1 of 6 financial statements was filed late (for 2020, 273 days late).

202523/04/2026
202426/06/2025
202320/06/2024
202228/06/2023
202108/07/2022
202015/07/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 183.73kMedianUSD 1.06mAverageUSD 22.40m

Net profit

This companyUSD 19.51kMedianUSD 37.33kAverageUSD 880.24k

Operating costs

This companyUSD 153.99kMedianUSD 922.77kAverageUSD 21.08m

Assets

This companyUSD 90.86kMedianUSD 608.93kAverageUSD 11.85m

Industry

Authorized Representatives

Georg Heinrich Zymella – President of the Management Board

Manner of representation

The company is represented by each member of the management board independently.

Ownership

Owner	Shares	Share value	Stake
Georg Heinrich Zymellaage 74	100	$1,350.62	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-09-17.

mBank
06 1140 1078 0000 5771 6200 1001
PKO Bank Polski
52 1020 2401 0000 0402 0651 8023
PKO Bank Polski
57 1020 2401 0000 0202 0651 8031

Debt

No entries in the National Debtors Register (KRZ).

Public aid

Grant date	Purpose	Gross amount	Granting body
Feb 21, 2023	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	––	Prezes Zakładu Ubezpieczeń Społecznych
Sep 8, 2022	De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier)	––	Prezes Zakładu Ubezpieczeń Społecznych

Competitors

Name	Revenue	Website
Bonopharmsp. z o.o.	$405,123.74	bonopharm.com
Wellnesssp. z o.o.	$317,458.51	welld.pl
Axonmedsp. z o.o.	$316,604.56	axonmed.pl
GSH Polskasp. z o.o.	$313,619.12	gshpolska.pl
Vorwarts Pharmasp. z o.o.	$210,138.62	vorwartspharma.pl
PRO Aktivsp. z o.o.	$164,060.83	proaktiv.pl
Biopharmaciasp. z o.o.	$154,706.20	biopharmacia.pl
BL Medicasp. z o.o.	$148,305.98	blmedica.pl
Naturaphsp. z o.o.	$145,244.74	naturaph.pl
Pharmbiopolsp. z o.o.	$99,211.10	pharmbiopol.com